脂質製劑市場－全球產業規模、佔有率、趨勢、機會及預測（依脂質來源、應用、通路、地區及競爭格局分類，2021-2031年）

全球脂質製劑市場預計將從 2025 年的 40.4 億美元成長到 2031 年的 67.2 億美元，複合年成長率為 8.85%。

這些製劑作為重要的藥物傳遞系統，利用脂質輔料溶解疏水性活性藥物成分，從而提高其在體內的吸收率。市場成長的主要驅動力是迫切需要提高難溶性候選藥物的生物利用度，以及生物製藥產業的蓬勃發展——該產業需要可靠的複雜分子載體。根據藥物化學及相關技術協會（DCAT）預測，2024年FDA核准的新藥中將有32%為生物製藥，這項數據表明，該產業越來越依賴脂質奈米顆粒等先進的遞送載體來確保療效。

儘管這些因素推動了強勁的發展勢頭，但該行業仍面臨著與產品技術耐久性相關的一些挑戰。可能阻礙市場擴張的一個主要挑戰是脂質製劑固有的物理化學不穩定性，這通常需要昂貴的生產過程和嚴格的儲存條件來防止劣化。

市場促進因素

mRNA疫苗和基因療法研發管線的快速成長正在從根本上改變市場格局，對先進脂質奈米顆粒（LNP）的需求空前高漲，以確保脆弱的核酸能夠順利遞送至細胞內並保持其穩定性。這一趨勢迫使藥物研發人員優先考慮脂質載體而非傳統賦形劑，因為這些先進的轉運體對於保護遺傳物質免受酵素分解至關重要。根據美國基因與細胞治療學會於2024年4月發布的《基因、細胞和RNA療法現狀：2024年第一季季數據報告》，全球基因、細胞和RNA治療方法開發平臺已擴展至4000多種，顯示市場對支持這些新一代療法的專用脂質製劑的需求將持續旺盛。

同時，越來越多的慢性病和腫瘤適應症正在加速脂質體系統的應用，以提高難溶性化療藥物的生物利用度並降低其全身毒性。製造商正利用這些製劑最大限度地提高增強滲透性和滯留效應（PERE），從而增加藥物在腫瘤部位的蓄積。大量患者亟需有效的治療，凸顯了這項龐大的需求。根據世界衛生組織（WHO）於2024年2月發布的《全球癌症負擔預測》，2022年全球將新增約2,000萬例癌症病例。市場對這些壓力的反應體現在對生產能力的大規模投資。例如，諾和諾德（Novo Holdings）於2024年以165億美元收購Catalent的協議，就反映了市場對確保複雜生物製藥遞送系統生產能力的高度重視。

市場挑戰

脂質製劑固有的物理化學不穩定性嚴重阻礙了全球市場的持續擴張。複雜的遞送系統，尤其是脂質奈米顆粒，極易發生氧化、水解和聚集等劣化過程，因此需要高度專業化、資本密集的生產流程和嚴格的低溫運輸物流。如果無法持續滿足這些嚴格的穩定性要求，則可能損害產品完整性，導致批次報廢和供應鏈中斷，從而造成重大經濟損失，直接限制市場擴充性。

生產線的這種脆弱性會帶來實際的經濟後果，阻礙經濟成長。技術穩定性方面的困難往往會導致生產中斷和關鍵治療藥物的大範圍供不應求，使企業無法充分滿足市場需求。根據美國衛生系統藥劑師協會預測，2024年該產業將出現創紀錄的323種藥品短缺，而這場危機通常是由與複雜無菌注射相關的品質和生產難題引發的。這些可靠性問題迫使製造商將投資轉向糾正措施和合規工作，而不是創新，最終減緩了整個產業的商業性發展進程。

市場趨勢

將複雜製劑的研發策略性外包給專業的合約研發生產機構 (CDMO) 正逐漸成為主流。這一趨勢的驅動力在於製藥公司需要在不承擔大量內部資本成本的情況下獲得專有技術。脂質奈米粒 (LNP) 等脂質基體系需要高度專業化的組裝平台，例如衝擊射流混合和微流體技術，以確保粒徑和包覆效率。因此，創新公司擴大與提供全面服務的契約製造合作。正如 CordenPharma 在 2025 年 10 月發表的報導《CDMO 的關鍵平台投資：產能和藥物模式》中所述，該公司於 2025 年 3 月透過其位於 Caponago 的工廠獲得 GMP 認證，從而加強了其脂質奈米粒技術。此前，該公司進行了策略性擴建，新增了約 900平方公尺的專業 GMP 生產空間。

同時，人工智慧在脂質製劑開發上的應用正在革新新型輔料的篩檢和最佳化。借助機器學習演算法，研究人員現在可以在電腦上預測數千種脂質結構的穩定性、毒性和轉染效率，從而顯著減少對傳統、費力的試驗試驗的依賴。這種數據驅動的方法對於設計能夠精準靶向特定組織並最大限度降低免疫抗原性反應的可電離脂質至關重要。根據2025年11月發表在《自然·生物技術》雜誌上的一項題為「利用人工智慧設計用於肺部基因治療的脂質奈米顆粒」的研究，研究人員利用深度學習策略成功評估了160萬種脂質結構，並篩選出能夠顯著提高mRNA有效載荷遞送效率的新型候選脂質。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球脂質製劑市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 依脂質來源（天然來源與化學合成）分類
  • 依應用領域（真菌感染疾病、腫瘤、基因治療、抗病毒疫苗等）
  • 按分銷管道（零售藥局、醫院藥局、網路藥局）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章 北美脂質製劑市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國家分析
  • 美國
  • 加拿大
  • 墨西哥

7. 歐洲脂質製劑市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國家分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

8. 亞太地區脂質製劑市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

9. 中東和非洲脂質製劑市場展望

• 市場規模及預測
• 市佔率及預測
• 中東和非洲：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

10. 南美洲脂質製劑市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國家分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進要素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 最新進展

第13章 全球脂質製劑市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的可能性
• 供應商電力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• ABITEC Corporation
• BASF
• Gattefosse
• CordenPharma
• Lipoid
• IOI Oleo GmbH
• Croda International
• Evonik Industries
• Ashland
• Merck KGaA

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Lipid Based Formulations Market is projected to increase from USD 4.04 Billion in 2025 to USD 6.72 Billion by 2031, reflecting a CAGR of 8.85%. These formulations serve as essential drug delivery systems, employing lipid excipients to solubilize hydrophobic active pharmaceutical ingredients and improve their absorption within the body. Market growth is chiefly driven by the urgent need to enhance the bioavailability of poorly water-soluble drug candidates and the growing biopharmaceutical sector, which demands reliable carriers for complex molecules. According to the Drug, Chemical & Associated Technologies Association, 32% of novel drugs approved by the FDA in 2024 were biologics, a statistic that highlights the industry's increasing reliance on advanced delivery vehicles like lipid nanoparticles to guarantee therapeutic efficacy.

Despite the robust momentum generated by these drivers, the sector encounters specific obstacles related to the technical durability of these products. A major challenge potentially hindering market expansion is the intrinsic physicochemical instability of lipid formulations, which frequently requires expensive manufacturing procedures and rigorous storage conditions to avoid degradation.

Market Driver

The rapid growth of mRNA vaccine and gene therapy pipelines is fundamentally transforming the market, creating an unparalleled requirement for advanced lipid nanoparticles (LNPs) to ensure the intracellular delivery and stability of delicate nucleic acids. This trend compels pharmaceutical developers to favor lipid-based carriers over conventional excipients, as these sophisticated vehicles are vital for shielding genetic material from enzymatic breakdown. As reported by the American Society of Gene & Cell Therapy in their 'Gene, Cell, & RNA Therapy Landscape: Q1 2024 Quarterly Data Report' in April 2024, the global pipeline has expanded to include over 4,000 gene, cell, and RNA therapies, indicating a lasting demand for specialized lipid formulations to support these next-generation treatments.

Simultaneously, the rising prevalence of chronic diseases and oncology indications is quickening the adoption of liposomal systems aimed at improving the bioavailability of poorly soluble chemotherapeutics and decreasing systemic toxicity. Manufacturers are utilizing these formulations to capitalize on the enhanced permeability and retention effect, thereby increasing drug accumulation at tumor sites. This critical demand is emphasized by the high volume of patients requiring effective care; according to the World Health Organization's 'Global Cancer Burden Estimates' from February 2024, there were approximately 20 million new cancer cases globally in 2022. The market's response to these pressures is evident in major investments in manufacturing capacity, such as Novo Holdings' 2024 agreement to acquire Catalent for $16.5 billion, reflecting the high value placed on securing production capabilities for complex biopharmaceutical delivery systems.

Market Challenge

The inherent physicochemical instability of lipid-based formulations poses a significant obstacle to the continued expansion of the global market. These complex delivery systems, particularly lipid nanoparticles, are susceptible to degradation processes such as oxidation, hydrolysis, and aggregation, which necessitate highly specialized, capital-intensive manufacturing operations and strict cold chain logistics. Failure to consistently maintain these rigorous stability requirements compromises product integrity, resulting in substantial financial losses from wasted batches and supply chain interruptions that directly limit market scalability.

This fragility in the production pipeline has tangible economic impacts that impede growth. The difficulty in ensuring technical robustness often leads to production halts and widespread availability issues for critical therapies, preventing companies from fully satisfying market demand. According to the American Society of Health-System Pharmacists, the industry faced a record high of 323 active drug shortages in 2024, a crisis frequently driven by quality and manufacturing hurdles associated with complex sterile injectables. Such reliability issues force manufacturers to redirect investment toward remediation and compliance rather than innovation, thereby slowing the overall commercial progress of the sector.

Market Trends

Strategic outsourcing of complex formulation development to specialized CDMOs is becoming a dominant trend, driven by the need for pharmaceutical companies to access proprietary technologies without incurring heavy internal capital costs. Because lipid-based systems such as LNPs require highly specialized assembly platforms like impingement jet mixing and microfluidics to ensure precise particle size and encapsulation efficiency, innovators are increasingly partnering with contract manufacturers that offer comprehensive capabilities. As noted by CordenPharma in the article 'CDMO Key Platform Investment in Capacity & Pharma Modalities' in October 2025, the company strengthened its lipid nanoparticle capabilities by obtaining GMP certification for its Caponago facility in March 2025, following a strategic expansion that added approximately 900 square meters of specialized GMP manufacturing space.

Concurrently, the integration of artificial intelligence into lipid formulation development is revolutionizing the screening and optimization of new excipients. By employing machine learning algorithms, researchers can now predict the stability, toxicity, and transfection efficiency of thousands of lipid structures in silico, significantly reducing reliance on traditional, labor-intensive trial-and-error experiments. This data-driven approach is critical for designing ionizable lipids that precisely target specific tissues while minimizing immunogenic responses. According to the study 'Artificial intelligence-guided design of lipid nanoparticles for pulmonary gene therapy' published in Nature Biotechnology in November 2025, researchers successfully utilized a deep-learning strategy to evaluate 1.6 million lipid structures, identifying novel candidates with significantly improved delivery efficiency for mRNA payloads.

Key Market Players

• ABITEC Corporation
• BASF
• Gattefosse
• CordenPharma
• Lipoid
• IOI Oleo GmbH
• Croda International
• Evonik Industries
• Ashland
• Merck KGaA

Report Scope

In this report, the Global Lipid Based Formulations Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Lipid Based Formulations Market, By Source of Lipids

• Natural v/s Chemically Synthesized

Lipid Based Formulations Market, By Application

• Fungal Diseases
• Oncology
• Gene Therapy
• Antiviral Vaccines
• Others

Lipid Based Formulations Market, By Distribution Channel

• Retail Pharmacies
• Hospital Pharmacies
• Online Pharmacies

Lipid Based Formulations Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Lipid Based Formulations Market.

Available Customizations:

Global Lipid Based Formulations Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Lipid Based Formulations Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Source of Lipids (Natural v/s Chemically Synthesized)
  • 5.2.2. By Application (Fungal Diseases, Oncology, Gene Therapy, Antiviral Vaccines, Others)
  • 5.2.3. By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Lipid Based Formulations Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Source of Lipids
  • 6.2.2. By Application
  • 6.2.3. By Distribution Channel
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Lipid Based Formulations Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Source of Lipids
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By Distribution Channel
  • 6.3.2. Canada Lipid Based Formulations Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Source of Lipids
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By Distribution Channel
  • 6.3.3. Mexico Lipid Based Formulations Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Source of Lipids
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By Distribution Channel

7. Europe Lipid Based Formulations Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Source of Lipids
  • 7.2.2. By Application
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Lipid Based Formulations Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Source of Lipids
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. France Lipid Based Formulations Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Source of Lipids
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. United Kingdom Lipid Based Formulations Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Source of Lipids
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By Distribution Channel
  • 7.3.4. Italy Lipid Based Formulations Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Source of Lipids
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By Distribution Channel
  • 7.3.5. Spain Lipid Based Formulations Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Source of Lipids
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By Distribution Channel

8. Asia Pacific Lipid Based Formulations Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Source of Lipids
  • 8.2.2. By Application
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Lipid Based Formulations Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Source of Lipids
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. India Lipid Based Formulations Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Source of Lipids
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. Japan Lipid Based Formulations Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Source of Lipids
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By Distribution Channel
  • 8.3.4. South Korea Lipid Based Formulations Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Source of Lipids
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By Distribution Channel
  • 8.3.5. Australia Lipid Based Formulations Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Source of Lipids
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By Distribution Channel

9. Middle East & Africa Lipid Based Formulations Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Source of Lipids
  • 9.2.2. By Application
  • 9.2.3. By Distribution Channel
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Lipid Based Formulations Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Source of Lipids
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. UAE Lipid Based Formulations Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Source of Lipids
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. South Africa Lipid Based Formulations Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Source of Lipids
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By Distribution Channel

10. South America Lipid Based Formulations Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Source of Lipids
  • 10.2.2. By Application
  • 10.2.3. By Distribution Channel
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Lipid Based Formulations Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Source of Lipids
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By Distribution Channel
  • 10.3.2. Colombia Lipid Based Formulations Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Source of Lipids
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By Distribution Channel
  • 10.3.3. Argentina Lipid Based Formulations Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Source of Lipids
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Lipid Based Formulations Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. ABITEC Corporation
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. BASF
• 15.3. Gattefosse
• 15.4. CordenPharma
• 15.5. Lipoid
• 15.6. IOI Oleo GmbH
• 15.7. Croda International
• 15.8. Evonik Industries
• 15.9. Ashland
• 15.10. Merck KGaA

16. Strategic Recommendations

17. About Us & Disclaimer